Marker Therapeutics (NASDAQ:MRKR) Upgraded at Brookline Capital Management

Brookline Capital Management upgraded shares of Marker Therapeutics (NASDAQ:MRKR) to a strong-buy rating in a research report released on Monday morning,Zacks.com reports.

Separately, LADENBURG THALM/SH SH raised their price target on Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a report on Monday, October 21st.

Marker Therapeutics Stock Up 2.6 %

Shares of NASDAQ:MRKR opened at $1.59 on Monday. The business’s 50 day moving average is $2.88 and its 200 day moving average is $3.24. Marker Therapeutics has a 12-month low of $1.48 and a 12-month high of $5.99.

Insider Buying and Selling

In other news, major shareholder Enterprise Associates 16 New bought 554,250 shares of the stock in a transaction dated Monday, December 23rd. The stock was purchased at an average cost of $3.20 per share, for a total transaction of $1,773,600.00. Following the transaction, the insider now owns 1,625,678 shares of the company’s stock, valued at $5,202,169.60. The trade was a 51.73 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Steve Elms acquired 11,085 shares of the stock in a transaction on Monday, December 23rd. The shares were acquired at an average price of $3.20 per share, with a total value of $35,472.00. Following the transaction, the director now directly owns 325,370 shares of the company’s stock, valued at $1,041,184. The trade was a 3.53 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 17.35% of the stock is owned by insiders.

Institutional Investors Weigh In On Marker Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRKR. Invst LLC purchased a new position in Marker Therapeutics in the third quarter valued at about $56,000. LPL Financial LLC purchased a new stake in Marker Therapeutics during the fourth quarter valued at approximately $248,000. Finally, Aisling Capital Management LP boosted its stake in Marker Therapeutics by 3.5% in the fourth quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock valued at $1,012,000 after acquiring an additional 11,084 shares in the last quarter. Institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.